Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 31 October

Sam Kanaan
October 31, 2023

Morning Bell 30 October

Grady Wulff
October 30, 2023

Weekly Wrap 27 October

Grady Wulff
October 27, 2023

Morning Bell 27 October

Sam Kanaan
October 27, 2023

Morning Bell 26 October

Grady Wulff
October 26, 2023

Morning Bell 25 October

Sophia Mavridis
October 25, 2023

Morning Bell 24 October

Sam Kanaan
October 24, 2023

Morning Bell 23 October

Grady Wulff
October 23, 2023

Weekly Wrap 20 October

Grady Wulff
October 20, 2023

Morning Bell 20 October

Sam Kanaan
October 20, 2023

Morning Bell 19 October

Grady Wulff
October 19, 2023

Morning Bell 18 October

Grady Wulff
October 18, 2023